Montagut C, et al. - It was demonstrated in this study that among patients with metastatic colorectal cancer (mCRC) and acquired anti-EGFR (epidermal growth factor receptor) resistance, continuous blockade of EGFR by Sym004 (which is a mixture of 2 nonoverlapping monoclonal antibodies targeting EGFR) did not improve overall survival in an unselected population of patients.